o_19ntugujs11ikbdrctt1teabbla.pdf

More documents

Recommendations

Info

6.1.2 PharmaMar Enters into Licensing Agreement with Janssen for Yondelis 6.1.3 Hana Enters into Licensing Agreement with Tekmira 6.1.4 AstraZeneca Enters into Licensing Agreement with Merck for MK-1775 6.1.5 Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug 6.1.6 Oasmia Enters into Licensing Agreement with Medison for Paclical 6.1.7 Orion Enters into Agreement with Oasmia 6.1.8 Ohio University Enters into Licensing Agreement with Phosplatin 6.1.9 Genta Enters into Licensing Agreement with Daiichi Sankyo 6.1.10 Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research 6.1.11 NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300 6.2 Co-development Deals 6.2.1 Bristol-Myers Squibb Enters into Co-development Agreement with Ono Pharma 6.2.2 Merck Enters into Co-development Agreement with Endocyte for Cancer Drug 6.2.3 Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate Centre 6.2.4 Almac Discovery Enters into an Agreement with Queen’s University Belfast for Drug Discovery 7 Appendix 7.1 All Pipeline Drugs by Phase 7.1.1 Discovery 7.1.2 Preclinical 7.1.3 IND/CTA-Filed 7.1.4 Phase I 7.1.5 Phase II
7.1.6 Phase III 7.1.7 Pre-Registration 7.2 Market Forecasts to 2020 7.2.1 Asia-Pacific 7.2.2 India 7.2.3 China 7.2.4 Japan 7.2.5 Australia 7.3 Abbreviations 7.4 Bibliography 7.5 Research Methodology 7.5.1 Coverage 7.5.2 Secondary Research 7.5.3 Primary Research 7.5.4 Therapeutic Landscape 7.5.5 Geographical Landscape 7.5.6 Pipeline Analysis 7.6 Expert Panel Validation 7.7 Contact Us 7.8 Disclaimer Latest Report:
Page 1 and 2: Ovarian Cancer Therapeutics in Asia
Page 3 and 4: 2 Introduction 2.1 Disease Pathophy
Page 5: 5.1.2 Treatment Use Patterns and Re
Page 9: Market Research Reports Search Engi

o_19ntugujs11ikbdrctt1teabbla.pdf

Create successful ePaper yourself

Delete template?

Save as template?